Join

Compare · MNKD vs NVS

MNKD vs NVS

Side-by-side comparison of MannKind Corporation (MNKD) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MNKD and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $282.64B, about 252.0x MNKD ($1.12B).
  • Over the past year, MNKD is down 5.2% and NVS is up 28.9% - NVS leads by 34.0 points.
  • MNKD has been more active in the news (19 items in the past 4 weeks vs 1 for NVS).
  • NVS has more recent analyst coverage (25 ratings vs 14 for MNKD).
PerformanceMNKD-5.16%NVS+28.88%
2025-06-11+0.00%2026-06-11
MetricMNKDNVS
Company
MannKind Corporation
Novartis AG
Price
$3.67+1.24%
$152.08+2.69%
Market cap
$1.12B
$282.64B
1M return
+11.87%
+2.61%
1Y return
-5.16%
+28.88%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2004
News (4w)
19
1
Recent ratings
14
25
MNKD

MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-ß inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Latest MNKD

Latest NVS